// App-Quantinova.ai

POS0443 (2021) : EXPLORING NOVEL TENOSYNOVITIS AND COMBINED INFLAMMATION IMAGING OUTCOMES: RESULTS FROM A RANDOMISED CONTROLLED TRIAL IN EARLY RHEUMATOID ARTHRITIS

Researchers

Presenter

  • P. G. Conaghan

Principal Investigators

  • M. stergaard

  • O. Troum

  • Z. Xie

  • A. Brett

  • M. Snyder

  • A. Ebrahim

  • D. Chapman

  • J. Andrews

Medical Centers

  • University of Leeds, Leeds Institue of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

  • National Institute for Health Research, Leeds Biomedical Research Centre, Leeds, United Kingdom

  • Rigshospitalet-Glostrup, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, Glostrup, Denmark

  • University of Copenhagen, Dept. of Forensic Medicine, Copenhagen, Denmark

  • University of Southern California Keck School of Medicine, Division of Rheumatology, Santa Monica, CA, United States of America

  • Pfizer Inc, Inflammation and Immunology, Peapack, NJ, United States of America

  • Imorphics Ltd, Clinical Trials Group, Manchester, United Kingdom

  • Pfizer Inc, Inflammation and Immunology, Peapack, NJ, United States of America

  • Pfizer Inc, Inflammation and Immunology, Peapack, NJ, United States of America

Locations

  • United Kingdom

  • Denmark

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • C reactive protein

Drug/Treatment

  • Tasocitinib

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • II

Study Id's

  • NCT01164579

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved